LONDON – Acacia Pharma Group plc became the second UK company in two weeks to postpone an IPO on the London Stock Exchange citing current uncertain market conditions. Read More
A fast-acting antidote for Boehringer Ingelheim GmbH’s blockbuster Pradaxa (dabigatran) won accelerated FDA approval Friday, becoming the first approved agent for reversing the widely used anticoagulant. Read More
Cempra Inc.’s stock (NASDAQ:CEMP) lost 28 percent of its value Friday to close at $19.29, down $7.49, as investors balked at infusion-site pain reactions reported in the otherwise successful, second phase III trial with solithromycin for community-acquired bacterial pneumonia (CABP). Read More
DUBLIN – Astrazeneca plc’s competitive efforts in type 2 diabetes, one of its key growth platforms, hit a setback when the FDA issued a complete response letter for its saxa/dapa combination of DPP-4 inhibitor saxagliptin and SGLT2 inhibitor dapagliflozin. Read More
Antioxidants were once the darlings of cancer prevention – and in some consumer health publications, they still are. Eat blueberries, drink coffee, live forever. Read More
RIO DE JANEIRO – Latin America still doesn’t have biotech clusters, an important tool to boost economic growth and drive research, said industry experts at the BIO Latin American conference recently, adding that, to succeed, the region will have to create the environment and the ecosystem to develop such clusters. Read More
A partial clinical hold placed by the FDA on two Zafgen Inc. trials following a participant’s death continued to hold company shares (NASDAQ:ZFGN) near an all-time low Friday, pushing them $10.66 lower, or 50.7 percent, to close at $10.36. Read More
Only the U.S. Senate can say for certain whether Robert Califf will be the next commissioner of the FDA, but the cardiologist is demonstrating some leadership on an agency function that has been a sore spot for many in industry: regulation of combination products, which combine drugs, devices and/or biologic materials. Read More
Hutchison China Meditech Ltd. (Chi-Med), of Hong Kong, filed an F-1 statement with the SEC seeking to list up to $100 million of its American depositary shares (ADS) on Nasdaq and trade under the ticker HCM. Read More
Arqule Inc., of Burlington, Mass., disclosed the publication of a paper detailing the preclinical profile of ARQ 092 and ARQ 751, orally available selective pan-AKT inhibitors. Read More
strong>Agios Pharmaceuticals Inc., of Cambridge, Mass., announced plans for multiple early stage combination studies of AG-220 and AG-221 in front-line acute myeloid leukemia (AML) during a special R&D day event. Read More
Two studies have shown that Ebola virus can persist in semen for at least nine months after an infection, and there is at least one case where Ebola virus in semen infected a survivor's sexual partner. Read More
